GlassScriptPhysician profile
Vernon B Chavez
NPI 1023101052
$4,212.94
in general payments reported to CMS, 2019-2025
29 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $832 · 2021: $642 · 2022: $394 · 2023: $567 · 2024: $749 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $804.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $512.05 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $474.99 | 2021-2025 | |
| Amgen INC. | $388.80 | 2019-2025 | Tavneos, Evenity, Prolia |
| Astellas Pharma US INC | $243.32 | 2020-2022 | |
| Mylan Specialty L.P. | $202.89 | 2019-2023 | Yupelri |
| Novo Nordisk INC | $191.02 | 2020-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $170.12 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $165.51 | 2020-2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $137.32 | 2019-2025 | Jardiance, Zepbound |
| Pfizer INC. | $134.88 | 2020-2023 | |
| Akebia Therapeutics INC | $123.44 | 2025 | Vafseo |
| Eisai INC. | $103.51 | 2021-2025 | |
| Allergan, INC. | $96.52 | 2020 | |
| Janssen Pharmaceuticals, INC | $82.58 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.64 | 2025 | Jardiance |
| Exact Sciences Corporation | $54.91 | 2024-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $47.42 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $35.08 | 2024 | Rexulti |
| Averitas Pharma INC. | $27.44 | 2025 | Qutenza |
| Viatris Specialty LLC | $24.96 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $22.79 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $17.56 | 2019 | |
| Corcept Therapeutics | $17.31 | 2025 | Korlym |
| Upsher-Smith Laboratories LLC | $16.95 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.76 | 2023 | Pyrukynd |
| Ironwood Pharmaceuticals, INC | $14.99 | 2020 | |
| Merck Sharp & Dohme LLC | $13.85 | 2021 | |
| Lucid Diagnostics INC. | $12.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.